Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Clinical trial NCT03637803 · TERMINATED

Trial details

NCT number: NCT03637803
Sponsor: 4D pharma plc
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Oncology Solid Tumor Non Small Cell Lung Cancer Renal Cell Carcinoma Melanoma Bladder Cancer

Start date: 2019-01-10
Primary completion: 2023-05-08
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.